Literature DB >> 32643601

Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020.

Lasse S Vestergaard1, Jens Nielsen1, Lukas Richter2, Daniela Schmid2, Natalia Bustos3, Toon Braeye3, Gleb Denissov4, Tatjana Veideman4, Oskari Luomala5, Teemu Möttönen5, Anne Fouillet6, Céline Caserio-Schönemann6, Matthias An der Heiden7, Helmut Uphoff8, Theodore Lytras9, Kassiani Gkolfinopoulou9, Anna Paldy10, Lisa Domegan11,12, Joan O'Donnell11, Francesca De' Donato13, Fiammetta Noccioli13, Patrick Hoffmann14, Telma Velez14, Kathleen England15, Liselotte van Asten16, Richard A White17, Ragnhild Tønnessen17, Susana P da Silva18, Ana P Rodrigues18, Amparo Larrauri19, Concepción Delgado-Sanz19, Ahmed Farah20, Ilias Galanis20, Christoph Junker21, Damir Perisa22, Mary Sinnathamby23, Nick Andrews23, Mark O'Doherty24, Diogo Fp Marquess25, Sharon Kennedy25, Sonja J Olsen26, Richard Pebody26, Tyra G Krause1, Kåre Mølbak1,27.   

Abstract

A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March-April 2020. Excess mortality particularly affected  ≥ 65 year olds (91% of all excess deaths), but also 45-64 (8%) and 15-44 year olds (1%). No excess mortality was observed in 0-14 year olds.

Entities:  

Keywords:  All-cause mortality; Covid-19 pandemic; EuroMOMO; Europe

Mesh:

Year:  2020        PMID: 32643601      PMCID: PMC7346364          DOI: 10.2807/1560-7917.ES.2020.25.26.2001214

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


We present pooled European-wide weekly mortality estimates from the European monitoring of excess mortality for public health action (EuroMOMO) network from the beginning of 2020 until week 18 (23 April–3 May) of this year. This period includes the initial 2 months of the coronavirus disease (COVID-19) pandemic in Europe, March and April, a time frame characterised by the end of the influenza season but widespread COVID-19 community transmission. We also calculate the weekly and cumulative excess all-cause mortality from week 1 to week 18/2020, and compare the results to the same period of the previous 4 years (2016, 2017, 2018, and 2019).

Relevance of excess mortality monitoring during the coronavirus disease pandemic in Europe

Following a coronavirus disease (COVID-19) outbreak in China in late December 2019, the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread rapidly to become a major global public health emergency [1,2]. On 11 March 2020, COVID-19 was declared a pandemic [3], which is currently still ongoing. In Europe, the first COVID-19 cases were reported in January 2020 in France [4]. During the following weeks, occurrences of cases and fatalities with rapidly increasing numbers were observed across many European countries [5,6]. By the end of June 2020 [7], about 1.6 million confirmed COVID-19 cases and 177,000 deaths had been officially reported from European Union (EU)/European Economic Area (EEA) countries and the United Kingdom (UK). The official national statistics on COVID-19 cases and deaths among European countries are heterogeneous, partly due to the differences in applied testing strategies and access to testing, and use of different reporting modalities. In this situation, numbers of excess all-cause deaths can provide a more complete and timely proxy measure of the mortality burden of COVID-19 in the population, in particular when there are no other factors known to cause excess mortality, such as seasonal influenza [8]. Since 2009, following the influenza A(H1N1)pdm09 pandemic, the EuroMOMO network (www.euromomo.eu) has monitored the weekly all-cause excess mortality in a large number of countries across Europe. EuroMOMO uses a statistical algorithm, which allows to compare and pool national mortality estimates [9]. The EuroMOMO mortality outputs form part of the routine monitoring of seasonal influenza severity in Europe, producing weekly and end-of-season reports to inform national and international public health agencies, and to evaluate mortality signals within and between countries in a systematic and timely manner [10-12]. Such outputs are particularly useful in the context of an emerging pandemic caused by a new infectious agent, where the true mortality burden is difficult to ascertain and compare between countries.

Estimating the number of all-cause deaths in EuroMOMO countries

Countries participating in the EuroMOMO network collect weekly data from civil registers or other official reporting sources on the number of deaths of all causes. The all-cause excess mortality, defined as the observed minus the expected numbers of deaths, is estimated using the EuroMOMO statistical algorithm, previously described in detail [9]. The EuroMOMO hub compiles these weekly data from individual countries and conducts a pooled analysis using an age-stratified method [13]. Currently, the following 24 European countries or federal states participate with their weekly data submission: Austria, Belgium, Denmark, England (UK), Estonia, Finland, France, Germany (Berlin and Hesse), Greece, Hungary, Ireland, Italy (19 cities), Luxembourg, Malta, the Netherlands, Northern Ireland (UK), Norway, Portugal, Scotland (UK), Spain, Sweden, Switzerland and Wales (UK). Ireland has encountered additional delays in death registrations during the pandemic period, hence the included numbers for this country are not yet complete. We present preliminary pooled European-wide mortality estimates from the EuroMOMO network for 2020. The pooled estimates cover the period until the end of week 18 (3 May)/2020, based on data received by the end of week 23 (7 June) of this year. Estimates are shown for all ages combined, and by the age groups 0–14, 15–44, 45–64, 65–74, 75–84, and ≥ 85 years. In addition to weekly all-cause mortality estimates, we also calculate the weekly and cumulative excess all-cause mortality for 2020 up to week 18, and compare the results with the same period in each of the previous 4 years (2016, 2017, 2018, and 2019) using our standard approach. Due to delay in death registration, the data for the most recent weeks beyond week 18 2020 are not included in the present report, but are available from the EuroMOMO website, where estimates corrected for delay in registration using a country-specific adjustment function are shown.

Ethical statement

Ethical approval was not needed for the study, which is based on surveillance data only.

Pooled estimates of all-cause excess mortality

All-cause mortality started to exceed normal expected levels in Italy around week 10 (1–8 March)/2020. In the following weeks, excess mortality was also detected in several other EuroMOMO countries, including the following: Belgium, England (UK), France, the Netherlands, Northern Ireland (UK), Portugal, Scotland (UK), Spain, Sweden, Switzerland and Wales (UK). While, during the same period of the COVID-19 pandemic, several other countries experienced no or only very limited excess mortality including: Austria, Denmark, Estonia, Finland, Germany (Berlin and Hesse federal states), Greece, Hungary, Luxembourg, Malta and Norway. The pooled mortality estimates for the 24 participating European countries or federal states showed an increasing trend during the first weeks of March 2020, and an excess mortality level higher than four z-scores above the baseline (defined as ‘substantial excess’) in week 11 (9–15 March)/2020 (Figure 1). The mortality was highest among individuals aged 65 years and older, but some countries also observed marked excess deaths among those aged 45–64 years, and some countries (in particular England and Spain) even noted excess mortality in the age group 15–44 years, also reflected in the overall pooled estimates. No excess mortality was observed in children aged 0–14 years.
Figure 1

EuroMOMO pooled estimates of all-cause mortality shown for all ages combined and by age group, week 1/2016−week 18/2020

EuroMOMO pooled estimates of all-cause mortality shown for all ages combined and by age group, week 1/2016−week 18/2020 EuroMOMO: European monitoring of excess mortality for public health action. Substantial excess mortality is defined as an excess level equivalent to four z-scores above the expected baseline. Mortality increased steeply in the next 3 weeks and peaked in all countries during week 14 (30 March–5 April)/2020, when a total of 88,581 deaths (all ages) was reached, translating into a z-score of 58. By week 15 (6–12 April)/2020 the mortality started a rapid decline, affecting all age groups except the 0–14 years where no excess mortality had been observed; however, by week 18/2020 a substantial mortality for all ages combined, of around 60,000 deaths, was still seen, corresponding to a z-score of 16 above the baseline. Figure 2 shows the weekly and cumulative pooled excess all-cause mortality estimates observed during the COVID-19 pandemic in comparison to the previous 4 years, from week 1 to week 18. At the peak level of mortality, in week 14, an excess of 35,802 deaths across all ages was estimated, of which 32,815 (92%) were persons aged ≥ 65 years. In comparison, the highest excess mortality in any week during the previous 4 years reached 16,165 deaths (all ages) in week 2 in 2017, i.e. during the severe 2016/17 influenza season [11] (Figure 2A).
Figure 2

EuroMOMO pooled estimates of excessa all-cause mortality shown combined for all ages and by age group, from week 1 to week 18 for year 2020, and week 1 to week 52 for the years 2016, 2017, 2018, 2019, respectively

EuroMOMO pooled estimates of excessa all-cause mortality shown combined for all ages and by age group, from week 1 to week 18 for year 2020, and week 1 to week 52 for the years 2016, 2017, 2018, 2019, respectively EuroMOMO: European monitoring of excess mortality for public health action. a Excess is defined as >2 z scores. The cumulative excess mortality from week 1 to week 18/2020 reached a total of 185,287 deaths (all ages), including 24,438 (13%) in persons aged 65–74 years, 55,226 (30%) in persons aged 75–84 years, and 88,598 (48%) in persons aged ≥ 85 years. The cumulative deaths in the younger age groups reached 14,339 (8%) in 45–64 year-old persons and 1,843 (1%) in 15–44 year-old persons. This period of the year includes a part of the usual influenza season. In comparison, the cumulative excess deaths (all ages) by week 18 reached 55,441 in 2019, 110,483 deaths in 2018, 83,009 deaths in 2017 and 29,849 deaths in 2016 (Figure 2B).

Discussion

Soon after its detection in China in late 2019, COVID-19 was found to lead to a considerable morbidity and mortality burden. A systematic review and meta-analysis resulted in an overall estimated proportion of severe cases of 25.6% and a case fatality rate (CFR) of 3.6%, with more severe clinical symptoms and higher CRF among older patients and patients with underlying medical conditions [14]. As increasing age and comorbidity appear to pose a risk for fatal outcome, it can be argued that COVID-19 mainly leads to death in patients with an expected short life span so that the overall excess mortality at the population level may be relatively limited. However, our analysis suggests that transmission of COVID-19 indeed has had a marked impact on all-cause mortality in the European population, despite the extensive societal preventive measures taken and the increase of treatment capacity in affected countries. We observed steep peaks in excess mortality in the age groups 65–74 years, 75–84 years and ≥ 85 years, respectively, considerably exceeding the excess mortality levels observed during any of the past influenza seasons monitored by EuroMOMO. Excess mortality was also observed in persons aged 45–64 years and 15–44 years, although to a much smaller extent than was seen among elderly people. No excess mortality was observed in children under 15 years old. When facing a new viral pandemic such as COVID-19, with many unknowns regarding biology and transmission potential, estimating the impact on public health in terms of disease severity and mortality is critical. With limited testing capacity, changing testing strategies and different surveillance and reporting systems, the officially reported mortality statistics based on individual COVID-19 death reports will inevitably be heterogeneous and incomplete. In this situation, estimating excess all-cause mortality using a standard approach across countries provides a powerful tool to rapidly obtain unbiased estimates of the COVID-19 mortality burden, and how it affects different age groups and different countries and areas. The mortality impact of the COVID-19 epidemic was clearly demonstrated by reports of the excess all-cause mortality estimates by the Ministry of Health in Italy in March 2020 [15,16], and by weekly all-cause mortality reports published early in the epidemic by the national health authorities of several other European countries. All-cause excess mortality is estimated in the current study. Considering the limited occurrence of seasonal influenza during the peak time of the COVID-19 mortality in the participating countries, and the absence of other major public health events, the estimated excess mortality can primarily be attributed to COVID-19. Some of these deaths may be directly related to COVID-19; others indirectly due to delays in accessing healthcare for other illnesses, and others due to other factors. The COVID-19 pandemic in Europe is not over yet, and in the coming weeks and months, as the national mortality data become more complete, more definitive estimates of the mortality burden of COVID-19 in Europe will be available and comparisons to previous influenza epidemics/pandemics and other public health events can be made. Similarly, observed discrepancies between all-cause mortality estimates and officially notified mortality statistics can be evaluated, to guide future COVID-19 case reporting and surveillance efforts. In the current COVID-19 pandemic situation, the EuroMOMO system has proven to be a valuable tool for timely detection and reporting of excess all-cause mortality across many parts of Europe in a coordinated and consistent manner. National and international organisations, the general public, media and others have largely drawn on EuroMOMO as a source of timely and easily accessible information about the evolving pandemic. The EuroMOMO network welcomes any country within Europe to become part of the network and thereby contribute to an even wider geographical coverage of the ongoing monitoring of the COVID-19 pandemic, from which new waves of transmission could occur. Importantly, the EuroMOMO statistical algorithm applied at the national level data provides countries with a simple and easy-to-use national mortality monitoring system. These mortality data are crucial for early warning and impact assessment, informing policy decisions and public health action.
  11 in total

1.  Excess mortality related to seasonal influenza and extreme temperatures in Denmark, 1994-2010.

Authors:  Jens Nielsen; Anne Mazick; Steffen Glismann; Kåre Mølbak
Journal:  BMC Infect Dis       Date:  2011-12-16       Impact factor: 3.090

2.  Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017.

Authors:  Lasse S Vestergaard; Jens Nielsen; Tyra G Krause; Laura Espenhain; Katrien Tersago; Natalia Bustos Sierra; Gleb Denissov; Kaire Innos; Mikko J Virtanen; Anne Fouillet; Theodore Lytras; Anna Paldy; Janos Bobvos; Lisa Domegan; Joan O'Donnell; Matteo Scortichini; Annamaria de Martino; Kathleen England; Neville Calleja; Liselotte van Asten; Anne C Teirlinck; Ragnhild Tønnessen; Richard A White; Susana P Silva; Ana P Rodrigues; Amparo Larrauri; Inmaculada Leon; Ahmed Farah; Christoph Junker; Mary Sinnathamby; Richard G Pebody; Arlene Reynolds; Jennifer Bishop; Diane Gross; Cornelia Adlhoch; Pasi Penttinen; Kåre Mølbak
Journal:  Euro Surveill       Date:  2017-04-06

3.  Mortality impacts of the coronavirus disease (COVID-19) outbreak by sex and age: rapid mortality surveillance system, Italy, 1 February to 18 April 2020.

Authors:  Paola Michelozzi; Francesca de'Donato; Matteo Scortichini; Manuela De Sario; Fiammetta Noccioli; Pasqualino Rossi; Marina Davoli
Journal:  Euro Surveill       Date:  2020-05

4.  First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020.

Authors:  Sibylle Bernard Stoecklin; Patrick Rolland; Yassoungo Silue; Alexandra Mailles; Christine Campese; Anne Simondon; Matthieu Mechain; Laure Meurice; Mathieu Nguyen; Clément Bassi; Estelle Yamani; Sylvie Behillil; Sophie Ismael; Duc Nguyen; Denis Malvy; François Xavier Lescure; Scarlett Georges; Clément Lazarus; Anouk Tabaï; Morgane Stempfelet; Vincent Enouf; Bruno Coignard; Daniel Levy-Bruhl
Journal:  Euro Surveill       Date:  2020-02

5.  Trends for influenza-related deaths during pandemic and epidemic seasons, Italy, 1969-2001.

Authors:  Caterina Rizzo; Antonino Bella; Cécile Viboud; Lone Simonsen; Mark A Miller; Maria Cristina Rota; Stefania Salmaso; Marta Luisa Ciofi degli Atti
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883

6.  European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?

Authors:  J Nielsen; L S Vestergaard; L Richter; D Schmid; N Bustos; T Asikainen; R Trebbien; G Denissov; K Innos; M J Virtanen; A Fouillet; T Lytras; K Gkolfinopoulou; M An der Heiden; L Grabenhenrich; H Uphoff; A Paldy; J Bobvos; L Domegan; J O'Donnell; M Scortichini; A de Martino; J Mossong; K England; J Melillo; L van Asten; M Ma de Lange; R Tønnessen; R A White; S P da Silva; A P Rodrigues; A Larrauri; C Mazagatos; A Farah; A D Carnahan; C Junker; M Sinnathamby; R G Pebody; N Andrews; A Reynolds; J McMenamin; C S Brown; C Adlhoch; P Penttinen; K Mølbak; T G Krause
Journal:  Clin Microbiol Infect       Date:  2019-02-18       Impact factor: 8.067

7.  Pooling European all-cause mortality: methodology and findings for the seasons 2008/2009 to 2010/2011.

Authors:  J Nielsen; A Mazick; N Andrews; M Detsis; T M Fenech; V M Flores; A Foulliet; B Gergonne; H K Green; C Junker; B Nunes; J O'Donnell; A Oza; A Paldy; R Pebody; A Reynolds; T Sideroglou; B E Snijders; F Simon-Soria; H Uphoff; L VAN Asten; M J Virtanen; F Wuillaume; K Mølbak
Journal:  Epidemiol Infect       Date:  2012-11-27       Impact factor: 4.434

8.  First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.

Authors:  Gianfranco Spiteri; James Fielding; Michaela Diercke; Christine Campese; Vincent Enouf; Alexandre Gaymard; Antonino Bella; Paola Sognamiglio; Maria José Sierra Moros; Antonio Nicolau Riutort; Yulia V Demina; Romain Mahieu; Markku Broas; Malin Bengnér; Silke Buda; Julia Schilling; Laurent Filleul; Agnès Lepoutre; Christine Saura; Alexandra Mailles; Daniel Levy-Bruhl; Bruno Coignard; Sibylle Bernard-Stoecklin; Sylvie Behillil; Sylvie van der Werf; Martine Valette; Bruno Lina; Flavia Riccardo; Emanuele Nicastri; Inmaculada Casas; Amparo Larrauri; Magdalena Salom Castell; Francisco Pozo; Rinat A Maksyutov; Charlotte Martin; Marc Van Ranst; Nathalie Bossuyt; Lotta Siira; Jussi Sane; Karin Tegmark-Wisell; Maria Palmérus; Eeva K Broberg; Julien Beauté; Pernille Jorgensen; Nick Bundle; Dmitriy Pereyaslov; Cornelia Adlhoch; Jukka Pukkila; Richard Pebody; Sonja Olsen; Bruno Christian Ciancio
Journal:  Euro Surveill       Date:  2020-03

9.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

10.  Updated rapid risk assessment from ECDC on the novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK.

Authors: 
Journal:  Euro Surveill       Date:  2020-03
View more
  76 in total

1.  Estimating under-recognized COVID-19 deaths, United States, march 2020-may 2021 using an excess mortality modelling approach.

Authors:  A Danielle Iuliano; Howard H Chang; Neha N Patel; Ryan Threlkel; Krista Kniss; Jeremy Reich; Molly Steele; Aron J Hall; Alicia M Fry; Carrie Reed
Journal:  Lancet Reg Health Am       Date:  2021-07-13

Review 2.  Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Authors:  Reem Hoteit; Hadi M Yassine
Journal:  Vaccines (Basel)       Date:  2022-06-09

3.  Excess Mortality During the COVID-19 Pandemic in Guatemala.

Authors:  Kevin Martinez-Folgar; Diego Alburez-Gutierrez; Alejandra Paniagua-Avila; Manuel Ramirez-Zea; Usama Bilal
Journal:  Am J Public Health       Date:  2021-09-23       Impact factor: 11.561

4.  Non-COVID outcomes associated with the coronavirus disease-2019 (COVID-19) pandemic effects study (COPES): A systematic review and meta-analysis.

Authors:  Vincent Issac Lau; Sumeet Dhanoa; Harleen Cheema; Kimberley Lewis; Patrick Geeraert; David Lu; Benjamin Merrick; Aaron Vander Leek; Meghan Sebastianski; Brittany Kula; Dipayan Chaudhuri; Arnav Agarwal; Daniel J Niven; Kirsten M Fiest; Henry T Stelfox; Danny J Zuege; Oleksa G Rewa; Sean M Bagshaw
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

5.  Hospital admission and mortality rates for non-covid diseases in Denmark during covid-19 pandemic: nationwide population based cohort study.

Authors:  Jacob Bodilsen; Peter Brønnum Nielsen; Mette Søgaard; Michael Dalager-Pedersen; Lasse Ole Zacho Speiser; Troels Yndigegn; Henrik Nielsen; Torben Bjerregaard Larsen; Flemming Skjøth
Journal:  BMJ       Date:  2021-05-24

6.  Temporal dynamic in the impact of COVID- 19 outbreak on cause-specific mortality in Guangzhou, China.

Authors:  Li Li; Dong Hang; Han Dong; Chen Yuan-Yuan; Liang Bo-Heng; Yan Ze-Lin; Yang Zhou; Ou Chun-Quan; Qin Peng-Zhe
Journal:  BMC Public Health       Date:  2021-05-08       Impact factor: 3.295

7.  [Impact of the COVID-19 pandemic: The point of view of patient associations].

Authors:  Mª D Navarro Rubio; J L Baquero Úbeda; A Mª Bosque García; S Alfonso Zamora; A Lorenzo Garmendia
Journal:  J Healthc Qual Res       Date:  2021-06-08

8.  Nine Months of COVID-19 Pandemic in Europe: A Comparative Time Series Analysis of Cases and Fatalities in 35 Countries.

Authors:  David Meintrup; Martina Nowak-Machen; Stefan Borgmann
Journal:  Int J Environ Res Public Health       Date:  2021-06-21       Impact factor: 3.390

9.  Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study.

Authors:  Ashleigh C Hamilton; David W Donnelly; Maurice B Loughrey; Richard C Turkington; Colin Fox; Deirdre Fitzpatrick; Ciaran E O'Neill; Anna T Gavin; Helen G Coleman
Journal:  Br J Cancer       Date:  2021-07-01       Impact factor: 9.075

10.  Local mortality estimates during the COVID-19 pandemic in Italy.

Authors:  Augusto Cerqua; Roberta Di Stefano; Marco Letta; Sara Miccoli
Journal:  J Popul Econ       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.